Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Michigan Rx Rebate Requirement For Non-Medicaid Programs Upheld By Appeals Court

This article was originally published in The Pink Sheet Daily

Executive Summary

D.C. federal appeals court affirms the lower court's rejection of PhRMA's arguments, citing the Supreme Court's decision in the group's case against Maine's prior authorization program. The court ruled that a link between Medicaid and non-Medicaid prices does not go against the "best interest" of Medicaid beneficiaries.

You may also be interested in...



State Rx Rebate Requirements For Non-Medicaid Populations Endorsed By Sen. Kerry

A Kerry Administration would support states’ use of Medicaid prior authorization lists to get non-Medicaid rebates. The Democratic Presidential candidate renews his call for reimportation from Canada at a campaign stop focused on drug costs.

State Rx Rebate Requirements For Non-Medicaid Populations Endorsed By Sen. Kerry

A Kerry Administration would support states’ use of Medicaid prior authorization lists to get non-Medicaid rebates. The Democratic Presidential candidate renews his call for reimportation from Canada at a campaign stop focused on drug costs.

Multi-State Medicaid Rx Pool Approved By HHS; $11 Mil. In Savings Estimated

First Health Services will administer the purchasing agreement for Michigan, Vermont, New Hampshire, Alaska and Nevada. The program will cover 900,000 beneficiaries.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel